大行评级|瑞银:上调诺诚健华目标价至12.3港元 重申“买入”评级

金融界
01 Apr

瑞银发表研报指, 诺诚健华良好销售势头预期可在今年持续,预计BTK抑制剂奥布替尼将继续在中国市场取得更多份额,加上公司多个项目研发将可能取得成果,看好未来前景,目标价从8.6港元上调至12.3港元,重申“买入”评级。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10